. Altered 5-HT signaling of the central nervous system contributes to the development of IBS-as indicated by the therapeutic effectiveness of both 5-HT3 receptor antagonists and tricyclic antidepressants 5, 6 . Enteric 5-HT interacts with 5-HT 3 receptors via afferent fibers that connect the gut with the central stress circuit (paraventricular nucleus, hippocampus, amygdala, locus coeruleus, and the raphe nucleus)
Irritable bowel syndrome (IBS) is a chronic gastroenterological disease of uncertain etiology marked by abdominal pain or discomfort and disorder of bowel movements. Albeit a common disorder, IBS exerts a negative impact on the quality of life and work productivity of patients 1 . While the pathophysiological mechanism of IBS remains incompletely elucidated, visceral hypersensitivity has been established as a key feature of IBS 2, 3 . Several neurotransmitters are linked to the pathophysiology of visceral hypersensitivity. The neurotransmitter 5-HT is synthesized in serotonergic neurons of the central nervous system(CNS) and possesses an important role in visceral hypersensitivity in patients with IBS 4 . Altered 5-HT signaling of the central nervous system contributes to the development of IBS-as indicated by the therapeutic effectiveness of both 5-HT3 receptor antagonists and tricyclic antidepressants 5, 6 . Enteric 5-HT interacts with 5-HT 3 receptors via afferent fibers that connect the gut with the central stress circuit (paraventricular nucleus, hippocampus, amygdala, locus coeruleus, and the raphe nucleus) 4 . These cerebral areas are abnormally activated due to chronic exteroceptive stress, leading to a local release of 5-HT, which may facilitate visceral pain processing via efferent fibers, and further result in visceral hypersensitivity 7 .
The 5-HT system of the brain is mainly concentrated in the raphe nucleus-the dorsal raphe nucleus (DRN) is the site of 5-HT synthesis in the brain 8 . Although the DRN is not the only participant of pain processing, it has a critical role in visceral pain modulation 9 . Ren et al. reported that visceral hypersensitivity in rats subjected to maternal separation (MS) is associated with elevated 5-HT and c-fos expression in the DRN in response to stress 10 . In contrast, downregulation of DRN serotonergic activity through electroacupuncture attenuates visceral hypersensitivity in MS rats 11 .
ScieNtiFic RepoRts | (2018) 8:9334 | DOI:10.1038/s41598-018-27592-x Nesfatin-1 is a anorectic neuropeptide processed from nucleobindin2 (NUCB2). Besides its homeostatic functions associated with food intake, mounting evidence indicates its role in the mediation of the stress response 12 . Central nesfatin-1 neurons are stimulated after restraint stress. Intracerebroventricular administration of nesfatin-1 activates corticotropin-releasing hormone (CRH), noradrenaline and 5-HT neurons, and induces the HPA axis 13 .
Previous studies by these authors demonstrated that nesfatin-1 is implicated in visceral hypersensitivity 14 . Furthermore, upregulated expression of nesfatin-1/NUCB2 in the amygdala results in visceral hypersensitivity in an MS model in rats 15 . Nesfatin-1 is colocalized with 5-HT in the DRN 16 . Rats exposed to MS manifested persistent IBS-like visceral hypersensitivity via elevated 5-HT expression in the DRN 10 . Furthermore, an intracerebroventricular injection of nesfatin-1 activates DRN 5-HT neurons 13 . These previous studies indicate that nesfatin-1 in the DRN may also have effects on visceral hypersensitivity, potentially through activation of DNR 5-HT neurons. In this study, we sought to determine the effect of nesfatin-1 in the DRN on visceral sensitivity using a maternally separated rat model of IBS. Antibodies against 5-HT and tryptophan hydroxylase (TPH, the rate-limiting enzyme for 5-HT synthesis) were used as markers of 5-HT neurons. Effects of nesfatin-1 on visceral hypersensitivity and DRN 5-HT neurons were studied.
Material and Methods
Animals and housing. Pregnant Sprague-Dawley rats were obtained from the Animal Core Facility, Nanjing Medical University (Nanjing, China), and were caged separately under controlled temperature (20 °C), with a 12 h/12 h light-dark cycle, and with free access to food and water. All experiments were carried out in Maternal separation. Female newborn pups were culled at the birth time. Male newborn rats were randomly allocated either to the MS group or the normally handled (NH) group. Each group contained three dams and 6-8 pups per litter. The MS protocol was applied as reported previously 17 . Briefly, pups in the MS group were placed into individual plastic cages with sawdust bedding maintained at 22 °C in a separate room to isolate them from their mothers for 3 h daily (8:00-11:00) from postnatal days 2 to 21, whereas pups in the NH group were undisturbed. After weaning on Day 22, 22 male pups in the MS group and 20 male pups in the NH group were housed by treatment group with 5 rats per cage until surgery at 8 weeks of age.
Experimental design. At the beginning of the experiment, when rats in the MS and NH group were 8 weeks of age, six rats in each group were randomly selected to evaluate visceral sensitivity. Then the remaining rats were prepared for DRN microinjection, the MS group was divided into 2 groups as anti-nesfatin-1/NUCB2 and vehicle, while NH group was designated as nesfatin-1 and vehicle respectively. pressures were quantified by AWR scores and electromyographic activities. Briefly, rats were sedated with isoflurane in a sealed cage. A distension balloon-made from a latex glove finger (5 cm in length) attached to a suction tube via a Y connector to a syringe pump and a sphygmomanometer-was inserted intrarectally 8 cm via the anus and secured to the tail. Rats were maintained in small Lucite cubicles(20 cm × 6 cm × 8 cm) and allowed to wake up and adapt for 20 min. CRD was carried out at graded intensities of 20, 40, 60, and 80 mmHg as previously described 18 . Each CRD stimulation period was sustained for 20 s, followed subsequently by a 2-min rest. AWR responses were measured by blinded observers who assigned AWR scores as follows: (1) normal behavior without response; (2) contraction of abdominal muscles; (3) lifting of abdominal wall; and (4) body arching and lifting of pelvic structures. To obtain EMG measurements of visceromotor responses, after the animals were anesthetized with 10% chlorohydrate (0.3 ml/100 g body weight, intraperitoneally), a pair of electrodes was stitched into the obliquus externus abdominis, tunneled subcutaneously, then exteriorized, and finally secured at the back of the neck. Rats were individually housed and recovered for 1 week after surgery. EMG signals were amplified and digitized with a PowerLab system (AD Instruments, New South Wales, Australia) and analyzed using Lab Chart 7. EMG activity was identified by the increase of the area under the curve (AUC) during 20 s of CRD over the baseline AUC (20 s before distension).
Stereotaxic cannulation.
Under anesthesia with 10% chlorohydrate (0.3 ml/100 g body weight, intraperitoneally), we implanted a 26-gauge guide cannula into the DRN at the following coordinates, AP = −8.0; L = 0.0, and DV = −5.8 (Paxinos and Watson) 19 , and then it was held in place with stainless steel screws and dental cement. For microinjection, an injection cannula (29 gauge), which was designed to protrude 1 mm beyond the guide, was inserted. Cannula/injection-site verification was done at the end of the experiment. Only rats having cannulas within the scope of the DRN were included in the data analysis. 1 animal in the MS group and 2 animals in the NH group with incorrect DRN targeting were excluded from the final analysis.The cannula/injection location is shown in Fig. 1 . Finally, two electrodes were implanted in the external oblique muscle as described above. Rats were individually housed, treated postoperatively for three days with analgesic dipyrone (100 mg/Kg) intramuscularly and recovered for 1 week after surgery.
Intra-DRN microinjection and visceral sensitivity testing. Seven days after surgery, intra-DRN injections were administered in accordance with the Paxinos and Watson atlas 19 . Rats in the MS model were microinjected with anti-nesfatin-1/NUCB2 (1 µL, 10 µg; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or vehicle (1 µL, sterile water) into the DRN; then, abdominal withdrawal reflex (AWR) scores and magnitude of electromyogram (EMG) were recorded 2 h later. While normal rats were microinjected with nesfatin-1 (1 µL, 50 pmol; Phoenix Pharmaceuticals, Burlingame, CA, USA) or vehicle (1 µL, sterile water) into the DRN, nesfatin-1 was injected daily for 7 consecutive days 15 then visceral sensitivity was detected at the 7th day.
Tissue preparation and immunohistochemistry. Immediately after completion of the experiments, under deep anesthesia with 10% chlorohydrate (0.3 ml/100 g body weight), rats were perfused with saline followed by 4% paraformaldehyde. Brains were quickly removed, immersed in the same fixative, and stored at 4 °C for 3-5 days. Thereafter, brains were paraffin embedded, and sections were cut at a thickness of 3 μm.
Immunohistochemistry was conducted following antigen retrieval using the Envision method. All sections were submerged in citrate buffer (pH 6.0) and heated in a pressure cooker for antigen retrieval. Slides were then incubated with a rabbit polyclonal anti-nesfatin-1 antibody (1:2400; cat#. H-003-22, Phoenix Pharmaceuticals), a mouse monoclonal anti-TPH antibody (1:1000; cat#. T0678, Sigma-Aldrich, USA), or a rabbit anti-5-HT antibody (1:8000; cat#. S5545, Sigma-Aldrich) at room temperature (RT) for 2 h. Secondary Envision Flex/HRP (horseradish peroxidase; Dako, 20 min) was added for signal amplification. Next, immunoreactivity was visualized with 3,3′-diaminobenzidine (DAB, Dako) before brief counterstaining with hematoxylin. The slides were dehydrated and mounted. Negative controls were set by omitting the primary antibody. Data Analysis and Statistics. All data are presented as the mean ± SE, Two-way repeated-measures ANOVA with Bonferroni post-hoc testing are used for colonic sensitivity analysis. Other data were analyzed by the Student's t-test. Significance was defined as p < 0.05.
Data availability.
The images and datasets generated and analyzed during the current study are available from the corresponding author on reasonable request. 
Nesfatin-1/NUCB2 and TPH immunoreactivity in the DRN of MS rats.
The MS rats showed an obvious and significant enhancement of nesfatin-1 and TPH immunoreactivity, compared to NH rats, in all sections of the DRN (representative images in Fig. 3A ). Image analysis quantification showed that the expression of nesfatin-1 (270.67 ± 60.82, in the MS group, vs 191.33 ± 45.87, in the NH group, p = 0.029; n = 6 for each group) or TPH (167.00 ± 29.75, in the MS group, vs 120.50 ± 33.99, in the NH group, p = 0.03; n = 6 for each group) was significantly elevated in the DRN of MS rats, as shown in Fig. 3B ,C.
Intra-DRN administration of anti-nesfatin-1/NUCB2 reduced visceral hypersensitivity.
To evaluate whether DRN nesfatin-1 is related to the regulation of visceral sensitivity, we observed AWR scores and EMG magnitude in response to graded strengths of CRD pressures in MS rats treated with anti-nesfatin-1/ NUCB2 or vehicle. We found that intra-DRN injection of anti-nesfatin-1/NUCB2 in MS rats resulted in a significant decline in the AWR scores at 40, 60, and 80 mmHg distension pressures [p = 0.015; p = 0.005; p < 0.001; n = 6 for each group] (Fig. 4A) and EMG magnitude at all distension pressures [p = 0.044; p = 0.024; p = 0.002; p < 0.001; n = 6 for each group] (Fig. 4B) , as compared with vehicle-treated rats.
Effects of intra-DRN administration of anti-nesfatin-1/NUCB2 on 5-HT neurons.
We observed 5-HT and TPH immunoreactivity in the DRN after application of anti-nesfatin-1/NUCB2 in MS rats. Representative images are presented in Fig. 5A . Intra-DRN injection of anti-nesfatin-1/NUCB2 led to a significant reduction of 5-HT-(88.67 ± 10.38, in the anti-nesfatin-1/NUCB2 antibody group, vs 120.00 ± 21.46, in the vehicle group, p = 0.009; n = 6 for each group) or TPH-(93.50 ± 20.42, in the anti-nesfatin-1/NUCB2 group, vs 137.00 ± 32.37, in the vehicle group, p = 0.019; n = 6 for each group) immunopositive cells in the DRN of MS rats (Fig. 5B,C) .
Effects of intra-DRN injection of nesfatin-1 on visceral sensitivity in normal rats. To identify
whether DRN nesfatin-1 contributes to the development of visceral hypersensitivity, we observed AWR scores and EMG magnitude in response to graded strengths of CRD pressures in normal rats treated with nesfatin-1 (50 pmol) or vehicle. We found that intra-DRN injection of nesfatin-1 in normal rats resulted in significantly elevated AWR scores [p = 0.008; p = 0.001; p < 0.001; n = 6 for each group] (Fig. 6A ) and EMG magnitude [p = 0.007; p = 0.039; p = 0.032; n = 6 for each group] (Fig. 6B) at 40, 60, and 80 mmHg distension pressures, relative to vehicle-treated rats.
Effects of intra-DRN injection of nesfatin-1 on 5-HT neurons. We observed 5-HT and TPH immunoreactivity in the DRN after application of nesfatin-1 in normal rats. Representative images are presented in Fig. 7A . After the intra-DRN injection of nesfatin-1 in normal rats, the number of 5-HT-(168.50 ± 54.62, in the nesfatin-1 group, vs 107.33 ± 27.59, in the vehicle group, p = 0.034; n = 6 for each group) or TPH-(146.00 ± 28.39, in the nesfatin-1 group, vs 100.33 ± 21.72, in the vehicle group, p = 0.011; n = 6 for each group) immunopositive cells in the DRN was significantly increased as compared with vehicle-injected rats in all sections of the DRN (Fig. 7B,C) .
Discussion
IBS is recognized as a stress-related disorder 20, 21 . Stress scores are higher in patients with IBS than with other functional bowel disorders, and stress is also significantly correlated with IBS symptoms 21 . A history of early adverse life events is more likely to result in IBS 22 . In our study, we used neonatal MS to establish a rat model of visceral hypersensitivity that mimics IBS. MS rats exhibited higher AWR scores and more intensive EMG magnitude at strengths of 40, 60, and 80 mmHg CRD pressure relative to controls. The present results indicate that MS produced persistent visceral hypersensitivity. Early-life stressors such as trauma, assault, disaster, various types of abuse, and chronic illness of a parent are related to IBS symptoms 23 . Coutinho et al. 24 evaluated the effects of a 3-h daily MS on visceral sensitivity, and demonstrated that neonatal stress predisposes adult rats to develop visceral hyperalgesia.
Nesfatin-1 is extensively located in the rat central nervous system; however, this mature peptide is not detectable in protein extracts from rat brain, and the nesfatin-1 receptor remains unknown 25 . Central or peripheral injection of nesfatin-1 in rats exerted an anorexic effect in a dose-dependent manner 26 . Furthermore, nesfatin-1 plays a regulatory role in the stress response 27 . Nesfatin-1 has been located widely in brain regions involved in stress mediation, such as the locus coeruleus, nucleus tractus solitarius (NTS), paraventricular nucleus (PVN), and nuclei of the amygdala and the DRN 12, 16 . Moreover, stress has a marked impact on visceral sensitivity 28 . We previously demonstrated central nesfatin-1 contributes to the formation of visceral hypersensitivity through interactions with glucocorticoid and mineralocorticoid receptors in the amygdala in rat MS models 15 . As yet, it remains unknown whether DRN nesfatin-1 is critical for visceral sensation. Furthermore, the DRN is strongly involved in pain modulation and nociresponsive neurons are present within this structure 29, 30 . Here, we show that MS rats exhibit elevated numbers of nesfatin-1-positive cells in the DRN. In addition, intra-DRN administration of anti-nesfatin-1/NUCB2 alleviated visceral hyperalgesia in MS model rats relative to vehicle-treated controls. In contrast, intra-DRN administration of nesfatin-1 produced visceral hyperalgesia with elevated AWR scores and EMG magnitude in normal adult rats. These results showed that nesfatin-1 in the DRN may be involved in the pathogenesis of MS-induced visceral hyperalgesia in rats.
5-HT is known to play a dominant role in the development of IBS through interaction with different receptors in the central or enteric nervous systems 31 . The DRN, a region rich in serotonergic neurons, represents cell bodies of the origin of the serotonergic system and projects widespread terminations into the forebrain and the brainstem 32 . MS induces an increase in 5-HT and cFos immunostaining in the DRN 10 , and there is higher turnover of 5-HT in the brainstem of MS rats as compared to NH animals 33 . In the present study, MS rats exhibit significantly elevated numbers of TPH-immunopositive cells in the DRN. The upregulated TPH expression in the DRN indicated that the biosynthesis of 5-HT itself may be increased, which in turn results in a dramatic elevation in the number of 5-HT neurons. These results indicate that MS results in hyperactivation of DRN 5-HT neurons.
Nesfatin-1 is colocalized with hypothalamic CRH neurons, brainstem noradrenaline, and 5-HT neurons 16 . Furthermore, intracerebroventricular administration of nesfatin-1 could activate CRH, noradrenaline, and 5-HT neurons 13 . We previously demonstrated that nesfatin-1 modulates visceral sensation in an IBS animal model, which may be mediated by the brain CRH/CRH1 signaling system 14 . As yet, it remains unknown whether nesfatin-1 leads to visceral hypersensitivity via 5-HT neurons in the DRN. In the present study, intra-DRN administration of anti-nesfatin-1/NUCB2 alleviated visceral hypersensitivity in MS model rats, accompanied by decreased 5-HT and TPH immunoreactivity in the DRN as compared with vehicle controls. These results demonstrated that the anti-hyperalgesic effect of anti-nesfatin-1/NUCB2 may be mediated by downregulated serotonergic activities in the DRN. However, intra-DRN administration of nesfatin-1 induced visceral hypersensitivity in normal rats, which correlated with elevated 5-HT and TPH immunoreactivity in the DRN. Taken together, nesfatin-1 could serve as a stress mediator-that is, stress may stimulate DRN nesfatin-1, which further activates DRN serotonergic neurons, evoking visceral hypersensitivity.
Hypersensitivity induced by visceral distension has been widely demonstrated in IBS, which can be associated with abnormal processing, modulation, and sensation of gut signals in the brain 34, 35 . Drossman et al. 36 discovered that poor clinical status in patients with IBS are associated with abnormal activation of the cingulate cortex. A meta-analysis of brain activation revealed that patients with IBS have exaggerated activation in the cerebral emotional arousal regions (anterior cingulate cortex and amygdala), and endogenous pain regulation regions (the midbrain) following visceral stimulation, as compared with controls 37 . These brain areas are heavily innervated by 5-HT neurons arising from the DRN 7 . The activation of the DRN 5-HT neurons in this IBS rat model may indicate their role in pain regulation and, moreover, because of their widespread projections, roles in other regions of the central nervous system.
Our study demonstrated that nesfatin-1 in the DRN has critical effect on visceral hyper -sensitivity in male maternally separated rats. MS induces colonic barrier dysfunction and mucosal inflammation in the colon 38 . However, nesfatin-1 and nesfatinergic neurons have anti-inflammatory actions 39 , peripheral colonic inflammation may stimulate central nesfatinergic system to ameliorate the inflammatory process. In the present study, we speculated that the neuroprotective effect of nesfatin-1 was not able to neutralize its role on visceral hypersensitivity.
In summary, Nesfatin-1 has a critical effect on visceral hypersensitivity, the underlying mechanism of which might be related to the activation of DRN 5-HT neurons.
